'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD.
Mastellos DC, et al. Among authors: connolly es.
Nat Immunol. 2019 Nov;20(11):1409-1413. doi: 10.1038/s41590-019-0503-1.
Nat Immunol. 2019.
PMID: 31562490
Free PMC article.